Carlos Alban - AbbVie Executive Vice President - Commercial Operations
| ABBV Stock | MXN 3,535 63.07 1.82% |
President
Mr. Carlos Alban is Vice Chairman, Chief Commercial Officer of the Company. Mr. Alban is AbbVie Executive Vice President, Commercial Operations. He served as Abbott Senior Vice President, Proprietary Pharmaceutical Products, Global Commercial Operations from 2011 to 2012, as Senior Vice President, International Pharmaceuticals from 2009 to 2011, as Vice President, Western Europe and Canada from 2007 to 2009, and as Vice President, European Operations from 2006 to 2007 since 2018.
| Age | 55 |
| Tenure | 6 years |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
AbbVie Management Efficiency
The company has return on total asset (ROA) of 0.0927 % which means that it generated a profit of $0.0927 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7529 %, meaning that it generated $0.7529 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | PRESIDENT Age | ||
| Matthew Ellis | Verizon Communications | 52 | |
| Manish Bhatia | Micron Technology | 51 | |
| David Zinsner | Micron Technology | 49 | |
| Andrew Iaboni | McEwen Mining | 41 | |
| Scott DeBoer | Micron Technology | 57 | |
| Brady Connor | Verizon Communications | N/A | |
| April Arnzen | Micron Technology | 47 | |
| Joel Poppen | Micron Technology | 54 | |
| Michael Bokan | Micron Technology | 62 | |
| Sumit Sadana | Micron Technology | 54 | |
| Hans Vestberg | Verizon Communications | 58 | |
Management Performance
| Return On Equity | 0.75 | |||
| Return On Asset | 0.0927 |
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carlos Alban, Executive Vice President - Commercial Operations | ||
| Robert Michael, Chief Financial Officer, Senior Vice President | ||
| Jeffrey Stewart, Senior Vice President U.S. Commercial Operations | ||
| Brett Hart, Independent Director | ||
| William Chase, Executive Vice President - Finance and Administration | ||
| Roxanne Austin, Independent Director | ||
| Perry Siatis, Gen VP | ||
| Azita SalekiGerhardt, Executive Vice President - Operations | ||
| Scott Reents, VP CFO | ||
| Thomas Freyman, Independent Director | ||
| Edward Rapp, Independent Director | ||
| Richard Gonzalez, Chairman of the Board, Chief Executive Officer | ||
| Brian Durkin, Vice President Controller | ||
| Frederick Waddell, Independent Director | ||
| Robert Alpern, Independent Director | ||
| Thomas Hudson, VP Officer | ||
| Glenn Tilton, Lead Independent Director | ||
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | ||
| Elizabeth Shea, VP Relations | ||
| Rebecca Roberts, Independent Director | ||
| Edward Liddy, Independent Director | ||
| William Burnside, Independent Director | ||
| Timothy Richmond, Chief Human Resource Officer, Executive Vice President | ||
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | ||
| Laura Schumacher, Executive Vice President - Business Development, External Affairs, General Counsel | ||
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | ||
| Melody Meyer, Independent Director |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.75 | |||
| Return On Asset | 0.0927 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 6.83 T | |||
| Shares Outstanding | 1.77 B | |||
| Shares Owned By Insiders | 0.11 % | |||
| Shares Owned By Institutions | 70.81 % | |||
| Price To Earning | 36.97 X | |||
| Price To Book | 18.09 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.